Conavi Medical and Minnetronix Medical Publish In-Depth Collaboration Review
07 1월 2025 - 9:00PM
Conavi Medical Corp. (TSXV: CNVI; OTC: CNVIF) (“
Conavi
Medical” or the “
Company”), a commercial
stage medical device company focused on designing, manufacturing,
and marketing imaging technologies to guide common minimally
invasive cardiovascular procedures, is pleased to announce the
publication of a detailed review of its collaboration with
U.S.-based Minnetronix, a world leader in high-precision medical
device manufacturing. Published in the industry journal, Medical
Design & Development, the article was co-authored by Tom Looby,
Conavi Medical’s CEO and Darcy Hart, Minnetronix Medical’s Director
of Optical Products.
“We’re leveraging our next-generation technology
with Minnetronix’s deep product engineering experience,” commented
Tom Looby. “Their expert team helped us improve every dimension of
performance while optimizing for manufacturability and cost. With
the new European interventional cardiology guidelines strongly
recommending intravascular imaging and the expectation that U.S.
guidelines will follow suit, we have an extraordinary opportunity
in a market where 80% of procedures still rely on old technology.
Conavi’s unique, no-compromise dual imaging solution is the right
product in the right place at the right time.”
The article is available at:
medicaldesigndevelopment.com/topics/imaging/article/22928873/how-conavi-and-minnetronix-combined-ivus-and-oct-into-one-dualbeam-imaging-system
Cautionary Statement Regarding
Forward-Looking Information
This news release contains “forward-looking
statements” within the meaning of applicable Canadian and U.S.
securities laws, which reflect the current expectations of
management of Conavi’s future growth, results of operations,
performance and business prospects and opportunities.
Forward-looking statements are frequently, but not always,
identified by words such as “may”, “would”, “could”, “will”,
“anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”,
“potential for” and similar expressions, although these words may
not be present in all forward-looking statements. Forward-looking
statements that appear in this release may include, without
limitation, references to Conavi’s plans for the commercialization
of its Novasight Hybrid™ System.
These forward-looking statements reflect
management’s current beliefs with respect to future events, and are
based on information currently available to management that, while
considered reasonable by management as of the date on which the
statements are made, are inherently subject to significant
business, economic and competitive uncertainties and contingencies
which could result in actions, events, conditions, results,
performance or achievements to be materially different from those
projected in the forward-looking statements. Forward-looking
statements involve significant risks, uncertainties and assumptions
and many factors could cause Conavi’s actual results, performance
or achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements. Such factors and assumptions
include, but are not limited to, Conavi’s ability to retain key
personnel; its ability to execute on its business plans and
strategies; and other factors listed in the “Risk Factors” sections
of the joint information circular of Conavi dated August 30, 2024
(which may be viewed at sedarplus.com). Should one or more of these
risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. These factors should be considered
carefully, and prospective investors should not place undue
reliance on the forward-looking statements.
Although the forward-looking statements
contained in the news release are based upon what management
currently believes to be reasonable assumptions and Conavi has
attempted to identify important factors that could cause actual
actions, events, conditions, results, performance or achievements
to differ materially from those described in forward-looking
statements, Conavi cannot assure prospective investors that actual
results, performance or achievements will be consistent with these
forward-looking statements. Except as required by law, Conavi
expressly disclaims any intention or obligation to update or revise
any forward-looking statements whether as a result of new
information, future events or otherwise. Accordingly, investors
should not place undue reliance on forward-looking statements. All
the forward-looking statements are expressly qualified by the
foregoing cautionary statements.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this press release.
Contacts
Stephen KilmerInvestor Relations(647)
872-4849stephen.kilmer@conavi.com
Stefano PiconeChief Financial Officer(416) 483-0100
Conavi Medical (TSXV:CNVI)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Conavi Medical (TSXV:CNVI)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025